GlassScriptPhysician profile
Anne W Marceau
NPI 1265482012
$2,610.04
in general payments reported to CMS, 2019-2025
22 companies · $864 in 2025
The $864 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $891 · 2022: $20.23 · 2023: $379 · 2024: $455 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.29 |
| Education | $347.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $790.89 | 2021-2024 | Brukinsa |
| Astellas Pharma US INC | $253.66 | 2021-2025 | Xtandi |
| Pfizer INC. | $221.22 | 2023-2025 | |
| Seagen INC. | $194.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $185.10 | 2021-2025 | Enhertu, Imfinzi |
| Janssen Biotech, INC. | $155.28 | 2023-2025 | Erleada, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $133.20 | 2023-2025 | Enhertu |
| Glaxosmithkline, LLC. | $115.78 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Emd Serono, INC. | $105.22 | 2023-2025 | Bavencio |
| Genmab U.S., INC. | $76.48 | 2024-2025 | Tivdak |
| Merck Sharp & Dohme LLC | $64.40 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Array Biopharma INC | $61.06 | 2025 | Braftovi, Mektovi, Lorbrena |
| Eisai INC. | $38.14 | 2024-2025 | |
| Beone Medicines USA, INC. | $34.86 | 2025 | Brukinsa |
| Genentech USA, INC. | $28.12 | 2023 | Tecentriq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.54 | 2025 | |
| Abbvie INC. | $25.90 | 2024 | |
| Novartis Pharmaceuticals Corporation | $23.76 | 2024 | |
| Karyopharm Therapeutics INC. | $23.20 | 2021 | |
| Lilly USA, LLC | $19.59 | 2024 | Retevmo, Jaypirca, Verzenio |
| Puma Biotechnology, INC. | $18.53 | 2025 | |
| Genzyme Corporation | $14.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Marceau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.